Apellis Pharmaceuticals Inc 2026年季度报告

WASHINGTON, DC 20549FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the transition period fromtoCommission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) 27-1537290(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) Registrant’s telephone number, including area code: (617) 977-5700 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Small reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of April 29, 2026, the registrant had 128,021,277 shares of common stock, $0.0001 par value per share, outstanding. APELLIS PHARMACEUTICALS, INC.FORM 10-QFOR THE QUARTER ENDED MARCH 31, 2026 TABLE OF CONTENTS PagePART I.FINANCIAL INFORMATION3Item 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss)for the three monthsended March 31, 2026 and 20254Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31,2026 and 20255Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20256Notes to Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3.Quantitative and Qualitative Disclosures About Market Risk35Item 4.Controls and Procedures35PART II.OTHER INFORMATION36Item 1.Legal Proceedings36Item 1A.Risk Factors36Item 5.Other Information38Item 6.Exhibits39Signatures40 Table of Contents Special Note Regarding Forward-Looking Statements and Industry Data This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Allstatements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statementsregarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectivesof management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements contain theseidentifying words. These forward-looking statements include, among other things, statements about: •our plans and expectations regarding the proposed acquisition of us by Biogen Inc., or Parent, pursuant to the agreementand plan of merger that we entered into with Parent and its wholly owned acquisition subsidiary on March 31, 2026,including the anticipated timeframe in which we expect to complete the transaction;•the ongoing commercialization of EMPAVELI and SYFOVRE;•our plans with respect to our ongoing and planned clinical trials for our product candidates, and preclinical studies,whether conducted by us or any future collaborators, including the timing of initiation, dosing of patients, enrollment andcompletion of these trials and expectations regarding the anticipated results from these clinical trials or preclinical studies;•our sales, marketing and distribution capabilities a